EXCLUSIVE: RenovoRx Concludes Enrollment in Phase 3 Trial of RenovoCath Drug-Delivery Device for Locally Advanced Pancreatic Cancer; Topline Data Readout Expected in 2H 2027

Loading news article.

EXCLUSIVE: RenovoRx Concludes Enrollment in Phase 3 Trial of RenovoCath Drug-Delivery Device for Locally Advanced Pancreatic Cancer; Topline Data Readout Expected in 2H 2027 | WAPE

EXCLUSIVE: RenovoRx Concludes Enrollment in Phase 3 Trial of RenovoCath Drug-Delivery Device for Locally Advanced Pancreatic Cancer; Topline Data Readout Expected in 2H 2027

Article summary

Related companies

Comments —